Therefore, the activation of signaling pathways triggered by IL-33 and IFN-α may be involved in the clinical manifestations specific to type 1 AIP and IgG4-RD, but not to SLE. Here, IL33 is linked to immunoglobulin G4-related sclerosing disease.